,,iii #aag? ,,congress #a/ ,session ,s4 ,,res4 #aea ,,9 ,,! ,,s5ate ,,( ,,! ,,unit$ ,,/ates ,april #ac1 #bjba,mr4 ,m]kley 7= himself1 ,mr4 ,s&]s1 ,ms4 ,w>r51 & ,mr4 ,book]7 submitt$ ! foll[+ resolution2 :i* 0 ref]r$ to ! ,committee on ,heal?1 ,education1 ,labor1 & ,p5sions ,,resolution ,call+ on ! ,presid5t & ! ,secret>y ( ,heal? & ,human ,s]vices to take action to l[] prescription drug co/s4 ,:]eas ! ,unit$ ,/ates is fac+ a p&emic1 & economic crisis1 caus$ by ! ,coronavirus ,disease #bjai 7,,covid-#ai7 t ?reat5s ! heal? & f9ancial well-be+ ( ne>ly e family 9 ! ,unit$ ,/ates2 ,:]eas ev5 be=e ! ,,covid-#ai p&emic1 consum]s & pati5ts 9 ! ,unit$ ,/ates 7 *>g$ high] prices = prescription drugs ?an consum]s & pati5ts 9 o!r c\ntries ar\nd ! _w2 ,:]eas families 9 ! ,unit$ ,/ates cont9ue to face f9ancial h>d%ip f unaf=dable out-(-pocket co/s & high] premiums t h be5 exac]bat$ by an economic crisis & losses 9 employ]-sponsor$ heal? cov]age2 ,:]eas #h 9 #aj individuals 9 ! ,unit$ ,/ates say ! co/ ( prescriptions is unreasonable1 & ne>ly #c 9 #aj individuals across ! ,unit$ ,/ates are ration+ _! m$ic9e due to high prescription drug co/s2 ,:]eas ! prescription drug co/ crisis has put families at risk = poor heal? outcomes1 increas+ ! likelihood ( complications f a sev]e case ( ,,covid-#ai = ^? families2 ,:]eas ev5 be=e ! ,,covid-#ai p&emic1 p ( color1 includ+ ,black1 ,br[n1 & indig5\s p1 7 disproportionately impact$ by high prescription drug co/s1 :i* 0 due 9 "p to a high] preval5ce ( *ronic conditions 9 ^? populations t require exp5sive prescription drugs2 ,:]eas p ( color1 includ+ ,black1 ,br[n1 & indig5\s p1 are dy+ at mu* high] rates z a result ( ,,covid-#ai1 & o!r diseases1 = :i* af=dable prescription drugs c & %\ld be available2 ,:]eas any price g\g+ by ph>maceutical companies is a root cause ( heal? disp>ities 9 ! ,unit$ ,/ates2 ,:]eas ne>ly #a 9 #c individuals 9 ! ,unit$ ,/ates fac+ increas$ prescription drug co/s sp5d less on basic necessities1 includ+ groc]ies1 to acc\nt = t increas$ prescription drug co/2 ,:]eas approximately #be p]c5t ( ! mon?ly premium = a heal? c>e consum] 9 ! ,unit$ ,/ates goes to prescription drug co/s2 ,:]eas m ?an #a 9 #d heal? c>e consum]s decl9e o!r m$ical te/s or proc$ures1 or put (f a visit to ! doctor's (fice1 because ( increas$ prescription drug co/s2 ,:]eas ph>maceutical companies abuse monopoly control grant$ by ! ,f$]al ,gov]nm5t1 9 ! =m ( pat5ts & regulatory exclusivities1 to limit competition & raise prescription drug co/s2 ,:]eas #h out ( #aj new drug pat5ts are = slight modifications to exi/+ drugs1 n = innovat+ new drug products2 ,:]eas #i out ( #aj ( ! l>ge/ ph>maceutical companies sp5d m on sales & m>ket+ ?an on rese>*+ new drugs2 ,:]eas ea* ( ! #cef drugs approv$ by ! ,food & ,drug ,adm9i/ration betwe5 #bjaj & #bjai 0 develop$ ?r\gh taxpay]-fund$ rese>* conduct$ by ! ,national ,in/itutes ( ,heal?2 ,:]eas ! #ah ph>maceutical companies on ! ,s,p #ejj sp5t m money on /ock buybacks & divid5ds ?an on rese>* & developm5t betwe5 #bjji & #bjah2 ,:]eas ! ph>maceutical & m$ical products indu/ry sp5t #bie1jjj1jjj on lobby+ 9 #bjai1 m ?an any o!r indu/ry & ne>ly d\ble ! next close/ indu/ry2 ,:]eas ! ph>maceutical indu/ry employs m lobbyi/s ?an !re are ,memb]s ( ,congress2 ,:]eas ! #be l>ge/ ph>maceutical companies 9 ! ,unit$ ,/ates a*ieve an av]age pr(it m>g9 above #bj p]c5t1 m ?an twice ! av]age pr(it m>g9 ( ! o!r #ejj l>ge/ companies 9 ! ,unit$ ,/ates2 ,:]eas ph>maceutical sp5d+ gr[? 9 ! ,unit$ ,/ates is project$ to outpace inflation = ! =eseeable future2 ,:]eas ph>maceutical companies rais$ ! price ( #bde drugs 9 ! fir/ #e mon?s ( ! ,,covid-#ai p&emic1 ) ! av]age price increase be+ #bc4h p]c5t2 ,:]eas #fa ( ! #bde prescription drugs t saw price hikes dur+ ! fir/ mon?s ( ! ,,covid-#ai p&emic 7 be+ us$ to treat ,,covid-#ai1 & ano!r #cj drugs 7 und]go+ cl9ical trials = use aga9/ t virus2 ,:]eas ne>ly #i 9 #aj adults 9 ! ,unit$ ,/ates said !y 7 conc]n$ ! ph>maceutical indu/ry w\ld use ! p&emic to raise prescription drug prices2 ,:]eas ! ,unit$ ,/ates sp5ds twice z mu* money on prescription drugs :5 comp>$ to o!r economically comp>able c\ntries1 includ+ ,canada1 ,france1 & ! ,unit$ ,k+dom1 despite pur*as+ few] drugs p] individual2 ,:]eas adults 9 ! ,unit$ ,/ates consi/5tly rank ! ph>maceutical indu/ry z _! lea/ lik$ indu/ry1 ) ! indu/ry be+ rank$ less favorably ?an ! oil1 bank+1 & airl9e indu/ries2 ,:]eas #h out ( #aj adults 9 ! ,unit$ ,/ates say prescription drug co/s are unreasonable & driv5 by ! desire = pr(its by ph>maceutical companies2 ,:]eas ! ,presid5t c lic5se g5]ic competition ) pat5t$ products :5 x is 9 ! public int]e/1 includ+ to combat abusive price g\g+ by l>ge ph>maceutical companies2 ,:]eas ! ,secret>y ( ,heal? & ,human ,s]vices 7ref]r$ to 9 ?is preamble z ! ,secret>y7 c require reasonable pric+ 9 return = receiv+ ,f$]al fund+ & o!r support = rese>* & developm5t2 & ,:]eas ! ,presid5t & ! ,secret>y c l[] prescription drug prices "u exi/+ law & au?orities3 ,n[1 !re=e1 be x ,t ! ,s5ate-- 7#a7 recognizes ! au?ority ( ! ,presid5t & ! ,secret>y ( ,heal? & ,human ,s]vices 7ref]r$ to 9 ?is resolution z ! ,secret>y7 to l[] prescription drug prices2 7#b7 calls on ! ,presid5t & ! ,secret>y to take adm9i/rative action to l[] prescription drug prices "u exi/+ law & au?orities1 includ+-- 7,a7 ,f$]al ,gov]nm5t use1 pursuant to section #adih7;a7 ( title #bh1 ,unit$ ,/ates ,code2 7,b7 m>*-9 rights1 pursuant to section #bjc ( title #ce1 ,unit$ ,/ates ,code2 7,c7 royalty-free rights1 pursuant to sections #bjb7;c77#d7 & #bji7;d77#a7 ( title #ce1 ,unit$ ,/ates ,code2 7,d7 ! ,c5t] = ,m$ic>e & ,m$icaid ,innovation1 e/abli%$ by section #aaae;,a7a77#a7 ( ! ,social ,security ,act 7#db ,u4,s4,c4 #acae;a7a77#a772 & 7,e7 all o!r exi/+ law & au?orities2 & 7#c7 enc\rages ! ,presid5t to use exi/+ law & au?orities to align prescription drug prices 9 ! ,unit$ ,/ates ) drug prices 9 o!r economically comp>able c\ntries1 includ+ ,canada1 ,france1 ! ,unit$ ,k+dom1 ,japan1 & ,g]many4